Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JALYN vs ATMEKSI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Treatment of symptomatic benign prostatic hyperplasia (BPH),Reduction in risk of acute urinary retention,Reduction in risk of need for BPH-related surgery
Treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg,Off-label use as part of antiretroviral therapy in treatment-experienced patients with viral suppression
1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.
1.5 mg/kg IV every 4 weeks
Dutasteride: 5 weeks (t½ ∼3-5 weeks) due to high tissue binding and slow elimination; Tamsulosin: 9-13 hours (t½ ∼9-13 h) in healthy subjects, prolonged in elderly (∼14-15 h).
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5. Tamsulosin is extensively metabolized by CYP3A4 and CYP2D6.
Atazanavir is metabolized by CYP3A4; cobicistat is metabolized by CYP3A and to a minor extent by CYP2D6.
Dutasteride: 40% renal, 60% fecal as metabolites; Tamsulosin: 76% renal (9% unchanged), 24% fecal as metabolites.
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Dutasteride: 99.0-99.5% bound to albumin and alpha-1-acid glycoprotein; Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
95% bound to albumin and alpha-1-acid glycoprotein.
Dutasteride: 300-500 L (∼3-4 L/kg); Tamsulosin: 16 L (∼0.2 L/kg). Dutasteride’s large Vd indicates extensive tissue distribution.
2.0 L/kg, indicating extensive tissue distribution.
Oral: Dutasteride ∼60% (capsule); Tamsulosin ∼90% (capsule, under fed conditions slightly reduced).
Oral: 60-70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to lack of data.
GFR 15-29 m L/min: 1.0 mg/kg IV every 4 weeks; GFR <15 m L/min: not recommended
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild to moderate impairment (Child-Pugh A or B), but use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: 1.0 mg/kg IV every 4 weeks; Child-Pugh C: not recommended
Not indicated for use in pediatric patients. Safety and efficacy not established.
Age 2-17 years: 1.5 mg/kg IV every 4 weeks; maximum 120 mg per dose
No specific dose adjustment recommended based on age alone. Monitor for orthostatic hypotension, dizziness, and falls risk, especially in elderly patients. Consider underlying renal and hepatic function.
No specific adjustment; monitor renal function and reduce dose if GFR <30 m L/min
None.
None
Use with caution in combination with other alpha-blockers due to risk of hypotension,Postural hypotension may occur, especially at initiation of therapy,Not recommended for use in women, children, or adolescents due to teratogenic risk,Evaluate for prostate cancer before initiating therapy,Dutasteride may increase risk of high-grade prostate cancer in some studies,Hepatic impairment may alter metabolism of dutasteride
Hepatotoxicity, especially in patients with pre-existing liver disease or elevated transaminases,Nephrolithiasis and cholelithiasis,Cardiac conduction abnormalities (PR interval prolongation),Risk of developing resistance if not used with other antiretrovirals,Renal impairment (cobicistat decreases estimated creatinine clearance)
Hypersensitivity to dutasteride, tamsulosin, or any component of the formulation,Use in women of childbearing potential,Use in pediatric patients
Concomitant use with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, rifampin, ergot derivatives, St. John's wort, lovastatin, simvastatin, sildenafil for pulmonary arterial hypertension),Severe hepatic impairment (Child-Pugh Class B or C)
Avoid grapefruit juice; may increase tamsulosin exposure and adverse effects. Administer with a meal (same meal consistency daily) to reduce tamsulosin-related adverse events. No other food interactions known.
Avoid alcohol (may exacerbate CNS effects). Grapefruit juice may increase atomoxetine exposure; limit consumption. High-fat meals do not significantly affect absorption.
JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abnormal development of external genitalia in male fetuses. Tamsulosin is an alpha-1 blocker with limited data but potential risks. First trimester: avoid; second and third trimesters: avoid due to theoretical risk.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis unless benefit outweighs risk.
JALYN is not indicated for use in women. Dutasteride and tamsulosin are excreted in rat milk but no human data. M/P ratio unknown; avoid breastfeeding due to potential adverse effects in infants.
Not recommended during breastfeeding. M/P ratio unknown. Excreted in animal milk; potential for serious adverse reactions in nursing infants.
No dose adjustments are applicable because JALYN is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are irrelevant as the drug should not be used.
No dose adjustment required in pregnancy. Pharmacokinetic profile unchanged.
Jalyn is a fixed-dose combination of dutasteride (5α-reductase inhibitor) and tamsulosin (α1-adrenergic antagonist) for symptomatic benign prostatic hyperplasia (BPH). Onset of symptom relief is faster than either agent alone. Tamsulosin component may cause orthostatic hypotension, especially in elderly patients; counsel to rise slowly. Dutasteride reduces serum prostate-specific antigen (PSA) by approximately 50% after 6 months; PSA levels should be interpreted accordingly. Avoid use in women of childbearing potential; dutasteride is teratogenic and can be absorbed through skin contact with capsules.
ATMEKSI (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) indicated for ADHD. It has a slower onset of action (2-4 weeks) compared to stimulants. Monitor for hepatotoxicity and suicidal ideation, especially in children and adolescents. Use cautiously with hepatic impairment (reduce dose) and CYP2D6 poor metabolizers (need lower dose). Avoid concurrent MAOIs. May cause orthostatic hypotension and urinary retention.
Take Jalyn 30 minutes after the same meal each day to maintain consistent absorption.,Do not crush, chew, or open capsules; swallow whole.,Avoid grapefruit juice, which may increase tamsulosin levels.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Report symptoms like fainting, severe headache, or prolonged painful erection (priapism) immediately.,Do not donate blood during therapy and for 6 months after stopping due to dutasteride transfer risk.,Use reliable contraception if partner is of childbearing potential; dutasteride can cause fetal harm.
Take ATMEKSI exactly as prescribed; do not change dose without consulting your doctor.,It may take 2-4 weeks to notice improvement in symptoms.,Avoid alcohol and grapefruit juice as they may affect drug levels.,Report any signs of liver problems (yellowing of skin/eyes, dark urine, abdominal pain) or suicidal thoughts immediately.,May cause dizziness or fainting, especially when standing up; rise slowly.,Do not stop abruptly without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JALYN vs ATMEKSI, answered by our medical review team.
JALYN is a 5-Alpha Reductase Inhibitor/Alpha-1 Blocker Combination that works by Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.. ATMEKSI is a PDE5 Inhibitor that works by ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JALYN and ATMEKSI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JALYN is: 1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.. The standard adult dose of ATMEKSI is: 1.5 mg/kg IV every 4 weeks. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JALYN and ATMEKSI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JALYN is classified as Category C. JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abn. ATMEKSI is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.